Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus recommendation of “Hold” by the ten research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $9.33.

Several brokerages have recently issued reports on FULC. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Finally, HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Fulcrum Therapeutics Stock Down 1.7 %

FULC opened at $3.96 on Friday. The stock’s 50 day moving average price is $3.51 and its two-hundred day moving average price is $5.92. The firm has a market capitalization of $213.60 million, a P/E ratio of -12.77 and a beta of 2.14. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently modified their holdings of the stock. National Bank of Canada FI grew its position in Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth about $59,000. Intech Investment Management LLC acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $62,000. Finally, Profund Advisors LLC bought a new position in Fulcrum Therapeutics during the 2nd quarter valued at about $68,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.